Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice

Shantaram S Joshi, Lora J. Messbarger, Weimin Hao

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In the present study, the immune status of syngeneic Balb/c animals bearing a poorly metastatic RAW117-P lymphoma and the highly malignant liver metastatic variant RAW117-H10 lymphoma were measured and compared to control animals with no known tumor. The immune status was evaluated by performing various analyses of spleen cells for the frequencies of immune cells using flow cytometry, in vitro mitogen response and in vitro NK cell-mediated cytotoxicity assays on days 6, 9 and 12 after tumor transplantation. The results of these studies indicated that from day 9 onwards, some of the immune response of the RAW117 lymphoma-bearing animals appeared to decrease compared to control animals. In order to boost the immune response of the tumor-bearing immunosuppressed animals, recombinant interleukin-2 (rIL-2) was administered to RAW117-H10 lymphoma-bearing animals. The immune status of tumor-bearing animals treated with rIL-2 was evaluated on days 5, 10 and 15 after tumor transplantation using similar analyses of spleen cells as described above. The results of these experiments indicated that IL-2 treatment increased splenic levels of cytotoxic cells, and decreased the in vivo tumorigenicity/metastasis of metastatic RAW117-H10 lymphoma cells. rIL-2 administration resulted in a significant increase in survival of tumor-bearing animals, and histological studies showed significantly lower tumor burdens in treated animals: it appears that rIL-2 has a beneficial therapeutic effect on immunosuppressive metastatic RAW117 lymphoma.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalClinical & Experimental Metastasis
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1994

Fingerprint

Interleukin-2
Lymphoma
Neoplasms
Therapeutics
Spleen
Transplantation
Therapeutic Uses
Immunosuppressive Agents
Tumor Burden
Mitogens
Natural Killer Cells
Flow Cytometry
Neoplasm Metastasis
Liver

Keywords

  • host immunosuppression
  • immunotherapy
  • interleukin-2
  • lymphoma
  • metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice. / Joshi, Shantaram S; Messbarger, Lora J.; Hao, Weimin.

In: Clinical & Experimental Metastasis, Vol. 12, No. 1, 01.01.1994, p. 37-46.

Research output: Contribution to journalArticle

Joshi, Shantaram S ; Messbarger, Lora J. ; Hao, Weimin. / Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice. In: Clinical & Experimental Metastasis. 1994 ; Vol. 12, No. 1. pp. 37-46.
@article{30035e19eede414eb26af199211605f9,
title = "Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice",
abstract = "In the present study, the immune status of syngeneic Balb/c animals bearing a poorly metastatic RAW117-P lymphoma and the highly malignant liver metastatic variant RAW117-H10 lymphoma were measured and compared to control animals with no known tumor. The immune status was evaluated by performing various analyses of spleen cells for the frequencies of immune cells using flow cytometry, in vitro mitogen response and in vitro NK cell-mediated cytotoxicity assays on days 6, 9 and 12 after tumor transplantation. The results of these studies indicated that from day 9 onwards, some of the immune response of the RAW117 lymphoma-bearing animals appeared to decrease compared to control animals. In order to boost the immune response of the tumor-bearing immunosuppressed animals, recombinant interleukin-2 (rIL-2) was administered to RAW117-H10 lymphoma-bearing animals. The immune status of tumor-bearing animals treated with rIL-2 was evaluated on days 5, 10 and 15 after tumor transplantation using similar analyses of spleen cells as described above. The results of these experiments indicated that IL-2 treatment increased splenic levels of cytotoxic cells, and decreased the in vivo tumorigenicity/metastasis of metastatic RAW117-H10 lymphoma cells. rIL-2 administration resulted in a significant increase in survival of tumor-bearing animals, and histological studies showed significantly lower tumor burdens in treated animals: it appears that rIL-2 has a beneficial therapeutic effect on immunosuppressive metastatic RAW117 lymphoma.",
keywords = "host immunosuppression, immunotherapy, interleukin-2, lymphoma, metastasis",
author = "Joshi, {Shantaram S} and Messbarger, {Lora J.} and Weimin Hao",
year = "1994",
month = "1",
day = "1",
doi = "10.1007/BF01784332",
language = "English (US)",
volume = "12",
pages = "37--46",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice

AU - Joshi, Shantaram S

AU - Messbarger, Lora J.

AU - Hao, Weimin

PY - 1994/1/1

Y1 - 1994/1/1

N2 - In the present study, the immune status of syngeneic Balb/c animals bearing a poorly metastatic RAW117-P lymphoma and the highly malignant liver metastatic variant RAW117-H10 lymphoma were measured and compared to control animals with no known tumor. The immune status was evaluated by performing various analyses of spleen cells for the frequencies of immune cells using flow cytometry, in vitro mitogen response and in vitro NK cell-mediated cytotoxicity assays on days 6, 9 and 12 after tumor transplantation. The results of these studies indicated that from day 9 onwards, some of the immune response of the RAW117 lymphoma-bearing animals appeared to decrease compared to control animals. In order to boost the immune response of the tumor-bearing immunosuppressed animals, recombinant interleukin-2 (rIL-2) was administered to RAW117-H10 lymphoma-bearing animals. The immune status of tumor-bearing animals treated with rIL-2 was evaluated on days 5, 10 and 15 after tumor transplantation using similar analyses of spleen cells as described above. The results of these experiments indicated that IL-2 treatment increased splenic levels of cytotoxic cells, and decreased the in vivo tumorigenicity/metastasis of metastatic RAW117-H10 lymphoma cells. rIL-2 administration resulted in a significant increase in survival of tumor-bearing animals, and histological studies showed significantly lower tumor burdens in treated animals: it appears that rIL-2 has a beneficial therapeutic effect on immunosuppressive metastatic RAW117 lymphoma.

AB - In the present study, the immune status of syngeneic Balb/c animals bearing a poorly metastatic RAW117-P lymphoma and the highly malignant liver metastatic variant RAW117-H10 lymphoma were measured and compared to control animals with no known tumor. The immune status was evaluated by performing various analyses of spleen cells for the frequencies of immune cells using flow cytometry, in vitro mitogen response and in vitro NK cell-mediated cytotoxicity assays on days 6, 9 and 12 after tumor transplantation. The results of these studies indicated that from day 9 onwards, some of the immune response of the RAW117 lymphoma-bearing animals appeared to decrease compared to control animals. In order to boost the immune response of the tumor-bearing immunosuppressed animals, recombinant interleukin-2 (rIL-2) was administered to RAW117-H10 lymphoma-bearing animals. The immune status of tumor-bearing animals treated with rIL-2 was evaluated on days 5, 10 and 15 after tumor transplantation using similar analyses of spleen cells as described above. The results of these experiments indicated that IL-2 treatment increased splenic levels of cytotoxic cells, and decreased the in vivo tumorigenicity/metastasis of metastatic RAW117-H10 lymphoma cells. rIL-2 administration resulted in a significant increase in survival of tumor-bearing animals, and histological studies showed significantly lower tumor burdens in treated animals: it appears that rIL-2 has a beneficial therapeutic effect on immunosuppressive metastatic RAW117 lymphoma.

KW - host immunosuppression

KW - immunotherapy

KW - interleukin-2

KW - lymphoma

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=0028031628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028031628&partnerID=8YFLogxK

U2 - 10.1007/BF01784332

DO - 10.1007/BF01784332

M3 - Article

C2 - 8287619

AN - SCOPUS:0028031628

VL - 12

SP - 37

EP - 46

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 1

ER -